Background: Red blood cell (RBC) transfusions are essential in health care. The quality of recommendations included in clinical practice guidelines (CPG), regarding this intervention, has not been systematically evaluated. This paper systematically assessed CPGs for RBC-transfusion, to appraise their methodological quality, to explore changes in quality over time, and to assess the consistency of the hemoglobin threshold (HT) recommendations.
About 85 million people are transfused annually, with considerable variation in the use of RBC-transfusion practices worldwide. 6 In spite of the efforts to standardize transfusion practice, as the publication of clinical practice guidelines, this variability in transfusion practices has persisted. For instance, while some CPGs have included recommendations focused on hemoglobin concentration to guide RBC-transfusion, other CPGs emphasize that transfusions should be provided in the presence of anemia symptoms and should not be based on hemoglobin concentration only. 2, 5, 8, 9 CPGs are defined as systematically developed statements to assist practitioner and patient decisions about appropriate health care. 12 International organizations have introduced and promote standards for the development of CPG, such as the Institute of Medicine (IOM), 13 World Health Organization (WHO), 14 National Institute for Health and Clinical Excellence (NICE), 15 Scottish Intercollegiate Guideline Network (SIGN), 16 and Guidelines International Network (G-I-N). 17 All these efforts provide resources to assist guideline developers in producing high-quality recommendations. Despite these initiatives, the quality of the CPGs and the adherence to methodological guidelines has been improved only lightly in the last decade. [18] [19] [20] [21] In the field of RBC-transfusion, a large body of clinical evidence has been generated; resulting in the publication of many CPGs. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] These
CPGs face with inconsistent recommendations that potentially result in confusion among clinicians, and the quality of the guidelines could be put to question. For these reasons, there is a need to assess the methodological quality of the CPGs in this field, to explain the variability of the recommendations. We conducted a systematic assessment of CPGs for RBC-transfusion, to appraisal their methodological quality using AGREE II tool, and to explore changes in quality over time, and to evaluate the consistency of hemoglobin concentration recommendations to guide transfusion.
METHODS

Data search
We searched for CPGs that included recommendations of RBCtransfusion in generic databases, compiler entities, registries, clearinghouses and guideline developers. We used free terms such as red blood cell transfusion, blood transfusion, anemia, and erythrocyte cells for these searches. For the MEDLINE search, via PubMed, we combined MeSH terms ("blood transfusion," "erythrocytes," "Erythrocyte Transfusion," "blood component transfusion," "anemia") and free terms (transfus* [tiab], transfusion requirements, RBC, RBCs, transfusion strategy, blood loss, blood conservation, transfusion of RBCs, red cell transfusion, management of anemia). Additionally, we used a series of terms related to guidelines as: "practice guideline," "consensus," "development conference," and "guideline." The search strategy and sources are listed in Table 1 .
Inclusion and exclusion criteria
We included (1) CPGs with recommendations related to hemoglobin concentration to guide the RBC-transfusion; (2) CPGs that performed a search in at least one database; and (3) CPGs published from 2006 until October 2017, in English or Spanish. We excluded (1) secondary publications like systematic reviews or meta-analyses and (2) CPGs with recommendations about pediatric patients (<15 years) and neonates.
Data collection
Two reviewers independently screened abstracts using the inclusion criteria stated above. If the inclusion criteria met, we retrieved the fulltext article and screened it to determine their eligibility. Two reviewers independently extracted the following data from each CPG: title, year, organization that developed the guideline, country of origin, and source of funding. In the case of disagreement, a third reviewer was consulted. One reviewer extracted the recommendation about hemoglobin threshold to guide transfusion, and the individual studies used to support the recommendation.
Quality assessment
We used the AGREE instrument to evaluate the quality of the included CPGs. [41] [42] [43] [44] This was developed primarily for guideline developers and researchers, to outline and measure the core elements of guideline development and implementation. The AGREE instrument (initially AGREE I, now AGREE II) contains 23 items, 41 spread over six domains: scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, and editorial independence, in addition to a final general item that evaluates the extent to which the guideline can be recommended for use in practice. To evaluate the items within the six domains, a 7-point Likert scale was used, ranging from "strongly disagree" to "strongly agree." For the overall assessment, we used a 3-point scale ranging from "not recommended" to "strongly recommended." Three independent reviewers, with experience in CGs assessment, applied the AGREE II instrument. In the case of disagreement, an agreement was reached by consensus. In the event of persistent disagreement, a fourth evaluator was consulted.
Statistical analysis
We performed a descriptive analysis of the CPGs according to the country of origin, the type of organization that developed them, the year of publication and the language of the CPGs. To establish the quality of each CG, the standardized score was calculated as a percentage; this was obtained by adding all the individual points from the items of a domain, and standardizing the total as a percentage of the maximum possible score from that area: (score obtained − minimum possible score)/(maximum possible score − minimum possible score) × 100. Once the quality of each CG was established, it was compared to the aforementioned descriptive variables. The degree of agreement between the reviewers was assessed using an intraclass correlation coefficient (ICC) with a 95% confidence interval (CI). Student's t-test compared the scores between different variables (date of publication and restrictive recommendations). For the analysis of the change in the global score over time, the date of publication was categorized into two 
RESULTS
Guideline characteristics
The search strategy provided 615 references after eliminating duplicates. A review of the titles and abstracts identified 47 potentially eligible CPGs. From the 47 examined CPGs, only 16 fulfilled the eligibility criteria and were included ( Table 2) . [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] One of these guidelines included four chapters that give the hemoglobin threshold recommendation for different settings. [34] [35] [36] [37] Included guidelines were published from 2008 to 2016. Six CPGs were from the United States, 23, 28, 29, 33, 40 four from the United Kingdom, 22, 31, 38, 39 one with four chapters from Australia, [34] [35] [36] [37] one from Canada, 24 Finland, 27 the Netherlands, 26 Singapore, 25 and Spain. 30 Twelve documents were developed by scientific societies, [22] [23] [24] [27] [28] [29] [30] [31] [32] [33] 39, 40 and seven CPGs were developed by government agencies. 25, 26, [34] [35] [36] [37] [38] Five of 16 included CPGs, focused solely on RBC-transfusion, [22] [23] [24] 31, 40 while there remaining 11 gave recommendations on blood products in general. [25] [26] [27] [28] [29] [30] [32] [33] [34] [35] [36] [37] [38] [39] Eight guidelines gave recommendations for general medical patients. [24] [25] [26] [27] 30, 35, 38, 40 The other 11 CPGs focused on specific populations: four on perioperative patients 22, 28, 33, 34 ; three on critically ill patients 23, 31, 36 ; two on obstetric patients 37, 39 ; one on patients with heart disease 32 ; and one on chronic kidney diseases patients. 29 For the analysis of recommendations, each chapter of one of the 
Quality assessment
The agreement between the three reviewers was high, with an ICC of 0.90 (95% CI: 0.81-0.96). Table 2 shows the standardized score of the AGREE II tool by domain and by guideline, as well as the overall evaluation. Additionally, Figure 1 shows the statistical summarized analysis of the total standardized score by domain.
TA B L E 2 CPG characteristics and hemoglobin threshold recommendations
Guideline Organization Year
Hemoglobin threshold recommendation
Country and language
Methods used to assess the quality and strength of the evidence Blood transfusion and the anesthetists. Red cell transfusion 22 The 
Domain 1: scope and purpose
This domain focuses on the general goal of the CPGs, considering the health condition, and the specific population for applying the guideline.
The average score was 59.4% (median = 62% and a range from 22.2% to 87%; Figure 1 ). Five CPGs (31%) scored above 70%. 23, 30, 32, 34, 38 See Table 2 for details about Domain 1.
Domain 2: stakeholder involvement
This domain assesses the working group that developed the CPGs, the involvement of stakeholders, and potential users. The average score was 43.2% (median = 40% and a range from 13% to 78%; Figure 1 ).
Only three CPGs (18.7%) scored more than 70 on this domain. 26, 29, 38 See Table 3 for details about Domain 2.
Domain 3: rigor of development
This domain addresses the process used to identify and summarize the evidence, the methodology to formulate recommendations, and their updates. The average score was 50% (median = 53% and a range from 9% to 87%; Figure 1 ). Four CPGs (25%) scored above 70% on this domain. 26, 29, 34, 38 See Table 3 for details about Domain 3.
Domain 4: clarity and presentation
This domain focuses on the wording, the structure, and the general format of the CPGs. The average score was 74.4% (median = 75% and a
TA B L E 3 AGREE II domain-standardized scores
Guideline
Scope and purpose
Stakeholder involvement
Rigor of development
Clarity of presentation
Applicability
Editorial independence
Overall recommendation
Blood transfusion and the anesthetists. 
TA B L E 3 (Continued)
Guideline
Scope and purpose
Stakeholder involvement
Rigor of development
Clarity of presentation
Applicability
Overall recommendation
The "Seville" document on consensus on the alternatives to allogenic blood transfusion range from 51% to 92.6%; Figure 1 ). Nine CPGs (56.2%) scored above 70% on this domain. 23, 25, 26, [29] [30] [31] [32] 34, 38 This domain scored the highest among the six domains included in the AGREE II instrument. See Table 3 for details about Domain 4.
Domain 5: applicability
This domain considers the barriers and facilitators for the implementation of the CPGs, including aspects of resources and adherence to the recommendations. The average score was 19.4% (median = 14% and a range from 0% to 54.2%; Figure 1 ). This was the lowest evaluated domain for all the CPGs, and none of the included CPGs scored above 70% on this domain. See Table 3 for details about Domain 5.
Domain 6: editorial independence
This domain assesses if funding sources influenced recommendations. The average score was 41% (median = 40% and a range from 0% to 86%; Figure 1 ). Four CPGs (25%) scored above 70% on this domain. 29, 32, 34, 38 See Table 3 for details about Domain 6.
Overall assessment
Three out of the 16 evaluated CPGs (18.7%) were "recommended"
by the independent evaluators, 29,34,38 6 CPGs (37.5%) were "recommended with modifications," 23, 26, 28, 30, 32, 40 and 7 CPGs (43.7%) were "not recommended" (see Table 3 ). 22, 24, 25, 27, 31, 33, 39 The three "recommended" CPGs scored ≥ 70% in the "rigor of development" domain.
The seven CPGs (18.7%) "not recommended" 22, 24, 25, 27, 31, 33, 39 by evaluators had scores below 70% in five of the six reported domains (see Table 3 ).
We did not find statistically significant differences in the AGREE II 
DISCUSSION
Summary of the main finding
In our review, we found 16 CPGs that met the eligibility criteria. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] In the overall CPGs' assessment, only 3 out of the 16 evaluated CPGs (18.7%) were "recommended" by the independent evaluators, 29,34,38 6
CPGs (37.5%) were "recommended with modifications," 23, 26, 28, 30, 32, 40 and 7 CPGs (43.7%) were "not recommended." 22, 24, 25, 27, 31, 33, 39 Most of the CPGs did not describe the literature search and selection methods, and they were ambiguous regarding how the evidence was appraized and whether or not the recommendations were truly evidence-based. The domains with the highest scores were "clarity and presentation" and "scope and purpose,"
and the domains with the lowest scores were "applicability" and "editorial independence" (see Table 3 and Figure 1 ). Only four CGs 26,29,34,38 scored ≥ 70% in the domain "rigor of development,"
which was considered one of the most critical domains, as it refers to methodological aspects concerning how the recommendations were developed.
In the analyzed CPGs, the use of a hemoglobin threshold for RBCtransfusion was variable. Some guidelines recommended restrictive strategies, and other CPGs avoided using a hemoglobin threshold, on the basis that RBC-transfusion should not be dictated by hemoglobin concentration alone. However, when the score in the rigor of development domain, of the CPGs recommending restrictive strategies, as compared with the CPGs that avoid giving a hemoglobin threshold, we did not find statistically significant differences. Therefore, the variability in recommendations cannot be explained by differences in this domain (P = 0.92). 
The context of this review with other literature
This review represents the first systematic assessment of the quality of clinical practice guidelines focused on red blood cell transfusion recommendations. Consistently with previous CPG evaluations in other clinical areas, [45] [46] [47] [48] the domains with the highest scores were "clarity of presentation" and "scope and purpose," whereas the domains with the lowest scores were "stakeholder involvement," "editorial independence," and "applicability." The lowest scores related to the "applicability" domain can be related to the belief that the activity of formulating recommendations was separated from the implementation processes.
Our results for the domains were similar to those of previous systematic assessment done by our group, that included the evaluation of 626
CPGs. 19 Specifically, in the "rigor of development" domain our review found low quality, with an average of 46.3% compared to 68% in other similar reviews. 19 
Strengths and limitations
Our systematic assessment has some limitations. First, although a robust set of search criteria was formulated and tested prior to full guideline identification, some CPGs might not have been adequately indexed as they were only used for institutional purposes, so we failed in their identification. We think that the quality of the CPGs not indexed in biomedical databases is probably lower compared to those indexed. Second, there is also a potential risk of selection bias because we included only studies that had been published in English or Spanish. To this extent, our assessment could be overestimating the quality of CPGs in RBC-transfusion. Third, the AGREE II 41-44 instrument has undergone some revisions since the development of the original AGREE instrument. 41 A 7-point scale is used instead of a 4-point scale for evaluating the items in the domains. This may have been a limitation in assessing the quality of the CPGs because the only well-defined points in the scale are 1 and 7. We found that the evaluators had difficulty in distinguishing between 3, 4, and 5 Likert values, which may have introduced a potential risk of reporting bias. However, the agreement among reviewers using the AGREE II instrument was high, with an ICC of 0.97.
On the other hand, we recognize some strengths of this systematic assessment. First, we are the first to assess the quality of development of clinical practice guidelines focused on red blood cell transfusion recommendations using methodological instruments that are widely recognized and accepted. Second, the uses of extensive search strategies, covering both indexed and gray literature and the use of expert appraisers who completed training and calibration to assess the quality of CPGs.
In conclusion, our findings show that much remains to be done to reach excellence in the area of CPGs on RBC-transfusion. Only three out of the 16 evaluated CPGs were "recommended" by the independent evaluators. Four domains ("stakeholder involvement," "rigor of development," "applicability," and "editorial independence") had serious shortcomings. The domains: "scope and purpose" and "clarity of presentation" were the more precisely reported.
Moreover, our study could not demonstrate statistical differences 
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